Page last updated: 2024-08-21

bufogenin and Colorectal Neoplasms

bufogenin has been researched along with Colorectal Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Bai, DL; Bai, JJ; Cao, GC; Gao, WD; Hao, TT; Ma, Y; Qi, WH; Shen, LD; Zong, XL; Zuo, CY1
Chen, C; Dai, Y; Han, Q; Jing, L; Liu, Y; Ma, Y; Sun, X; Wang, H1

Other Studies

2 other study(ies) available for bufogenin and Colorectal Neoplasms

ArticleYear
Resibufogenin inhibited colorectal cancer cell growth and tumorigenesis through triggering ferroptosis and ROS production mediated by GPX4 inactivation.
    Anatomical record (Hoboken, N.J. : 2007), 2021, Volume: 304, Issue:2

    Topics: Bufanolides; Carcinogenesis; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Colorectal Neoplasms; Ferroptosis; Humans; Oxidative Stress; Phospholipid Hydroperoxide Glutathione Peroxidase; Reactive Oxygen Species

2021
Resibufogenin suppresses colorectal cancer growth and metastasis through RIP3-mediated necroptosis.
    Journal of translational medicine, 2018, 07-20, Volume: 16, Issue:1

    Topics: Animals; Apoptosis; Bufanolides; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Humans; Mice; Necrosis; Neoplasm Metastasis; Receptor-Interacting Protein Serine-Threonine Kinases

2018